Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing.
Coronary stent implantation is the second great advance in the treatment of obstructive coronary artery disease since the introduction of balloon catheter angioplasty. However, in-stent restenosis (ISR) caused by neointimal hyperplasia has been a major limitation of stents, occurring in up to 30% of cases. Advances in coronary stent technology both in terms of stent design and function and especially drug-eluting stents (DES) have significantly improved the safety and efficacy of percutaneous coronary intervention (PCI) with stenting, including marked reduction in ISR. This has led to use of DES for increasingly challenging clinical and lesional subsets, with potential for increased risk of stent-associated complications, especially late stent thrombosis (LST). Because restenosis and stent thrombosis are caused by multiple and often interrelated factors, ideal agents for stent coatings should inhibit thrombus formation, inflammatory reaction, and cellular proliferation, while supporting reendothelialization. To avoid undesirable effects of currently applied (durable) polymers, biocompatible, and bioabsorbable polymers as well as DES delivery systems that minimize polymer burden have been produced and tested. Bioabsorbable stents, both polymeric and metallic, have been developed to decrease potential late complications after stent implantation. Novel strategies to address some of these challenges are in various stages of research and development. In this article we outline developments in the field of passive and active stent coatings and evaluate the ongoing role of such coatings in the contemporary era of DES.
Pendyala
Lakshmana
L
Saint Joseph's Translational Research Institute/Saint Joseph's Hospital of Atlanta, Georgia 30342, USA.
Jabara
Refat
R
Robinson
Keith
K
Chronos
Nicolas
N
D023903:Coronary Restenosis / Q000517:prevention & control; D023921:Coronary Stenosis / Q000188:drug therapy* / Q000601:surgery*; D016503:Drug Delivery Systems; D054855:Drug-Eluting Stents / Q000009:adverse effects / Q000145:classification; D006801:Humans; D011108:Polymers / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic; D013927:Thrombosis / Q000209:etiology
D011108:Polymers